BioNTech SE : Disappointing Q2 results – Strong cash position will help to capitalise on promising mRNA platform
>Q2 results below expectations - Write-offs by BioNTech’s collaboration partner Pfizer, substantially reduced the company’s gross profit share in Q2 and thus burdened BioNTech’s Q2 top and bottom line. As a result, company’s Q2 earnings, were significantly below expectations (and as expected substantially below 2022 levels due to the decreased demand for the company’s Covid vaccines – see table on next page). Revenue came in at € 168m vs ODOO BHF estimates of € 652m a...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.